Bladder preservation with trimodal therapy (TMT) has emerged as a feasible alternative to radical cystectomy in patients with muscle-invasive bladder cancer. Neoadjuvant chemotherapy (NAC) was proven to cause pathological downstaging.
To determine the use of surgical resection of metastatic disease in a large national sample and its association with overall survival. The National Cancer Database was queried for patients with metastatic bladder cancer (2004-2016).
Introduction The therapeutic landscape for urothelial carcinoma has changed significantly over the past few years with the addition of immunotherapy to platinum-based chemotherapy. Targeted therapy against FGFR (fibroblast growth factor receptor) is now also approved for the minority of patients with FGFR aberrations.
In response to the COVID-19 pandemic, New York State ordered the suspension of all elective surgeries to increase intensive care unit (ICU) bed capacity. Yet the potential impact of suspending elective surgery on ICU bed capacity is unclear.
(UroToday.com) Neoadjuvant systemic therapy is a widely established treatment paradigm for many malignancies. However, the use of androgen deprivation therapy is not widely endorsed in patients with non-castrate-resistant prostate cancer. The use of neoadjuvant hormonal therapy has been shown previously to improve pathological outcomes reducing positive surgical margins and increase the incidence of organ-confined disease. […]
(UroToday.com) Prostate cancer and testosterone deficiency symptoms increase with age. Therefore, patients may suffer from both conditions, and their quality of life could be significantly reduced. The EQUINOXE (NCT02630641) is an observational study in prostate cancer patients initiating GNRH agonist therapy and included 492 patients and their partners. The objective of this currently complimentary presented […]
(UroToday.com) Androgen deprivation therapy in prostate cancer is an effective treatment for a certain period of time and does improve prognosis. However, there is concern over long term side effects, including cardiovascular events. It has been shown that long-term androgen deprivation therapy increases the cardiovascular event rate. 20 to 30% of prostate cancer patients have pre-existing […]
(UroToday.com) Apalutamide is an oral non-steroidal anti-androgen agent that binds to the androgen receptor and prevents nuclear translocation, DNA binding, and androgen receptor-mediated transcription. In the phase three TITAN study, it was shown that apalutamide plus ADT significantly improved overall survival, radiographic progression-free survival, and time to prostate-specific antigen progression in a broad population of […]
(UroToday.com) The STAMPEDE trial recently demonstrated a survival benefit for selected patients with metastatic prostate cancer who were treated with androgen deprivation therapy plus prostate radiotherapy.1 This trial demonstrated that the treatment of the primary tumor improved as well as failure-free survival in patients with M1a prostate cancer. Furthermore, radiotherapy was associated with a survival benefit […]
(UroToday.com) The vast majority of patients who are newly diagnosed with Renal Cell Carcinoma (RCC) have localized disease (~75%). This proportion has continued to rise with the increasing utilization of cross-sectional imaging in the primary care and emergency department contexts. For patients who are fit for surgery, surgical resection (either via partial or radical nephrectomy) remains […]
